> "The preprint study funded by the companies determined that the vaccine’s effectiveness reached a high point of 96.2 percent within two months after the second dose."
The manufacturers are lobbying hard for booster shots, and there's no reason to trust a pre-print that they funded.
Anyway, I think our next dose in the US will likely be updated for Delta instead of a booster.
This is not a useful statement without including what the effectiveness endpoint is. The mRNA vaccines were miraculously effective against even symptomatic COVID due to the high antibody titers they generated but that was just a bonus. Their main objective has always been to prevent hospitalization and death. They continue to reduce these outcomes by >90% and there is no indication of this T-cell based immunity decreasing.
> "The preprint study funded by the companies determined that the vaccine’s effectiveness reached a high point of 96.2 percent within two months after the second dose."
The manufacturers are lobbying hard for booster shots, and there's no reason to trust a pre-print that they funded.
Anyway, I think our next dose in the US will likely be updated for Delta instead of a booster.